FDA Requiring Labeling Changes for Benzodiazepines

The U.S. Food and Drug Administration announced that it is requiring an update to the Boxed Warning, and requiring class-wide labeling changes for benzodiazepines to include the risks of abuse, addiction, physical dependence and withdrawal reactions. This action is part of the FDA’s ongoing effort to promote public health by minimizing risks associated with inappropriate use of controlled substances.#FDA#benzodiazepine#substanceawareness